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Purpose: The goal of this study was to determine the adherence of glaucoma patients to their 
topical glaucoma medication. Furthermore, the relationships between the adherence behavior 
and the patients’ demographic data, clinical characteristics, and their knowledge about glaucoma 
were evaluated.
Methods: This was a prospective study of 123 patients with primary open-angle glaucoma who 
were given two standardized questionnaires. The first questionnaire at time point T1 comprised 
a knowledge assessment and the self-reported adherence measures Adherence to Refills and 
Medication Scale 2 (ARMS2), visual analogue scale for adherence (VAS-AD), and missed doses 
in the past 14 days. Two months later at time point T2, a second questionnaire reevaluated the 
adherence measures ARMS2, VAS-AD, and missed doses in the past 14 days.
Results: There was a good correlation among all the three adherence measures at T1 and T2. The 
mean values of ARMS2 were in the lower range, with 3.38 at T1 and 2.8 at T2. The VAS-AD 
detected that 18.5% of patients always took their eye drops correctly, and 77.9% of patients 
reported not to have missed a single dose in the past 14 days. There was no significant correla-
tion between the patients’ demographic data or knowledge about glaucoma and the adherence 
measures ARMS2 or VAS-AD. Among the clinical characteristics, only single-eye blindness 
showed a significant correlation with VAS-AD.
Conclusion: In this study, no general relationships were found between medication adherence 
and the patients’ demographic data, clinical characteristics, or knowledge about glaucoma. It may 
be assumed that more individualized strategies are required to optimize adherence behavior. 
Keywords: adherence, eye drops, glaucoma, medication
Introduction
Primary open-angle glaucoma (POAG) is a leading cause of blindness in the world.1,2 
This disease is characterized by elevated intraocular pressure (IOP) and a progres-
sive loss of nerve fibers, leading to optic nerve degeneration. The medical therapy 
for POAG is based on the regular use of hypotensive eye drops to decrease the IOP. 
A major determinant for success in medical therapy is the adherence of patients to 
their medication.3 Adherence is defined as the extent to which a patient’s behavior 
in taking medication corresponds with agreed recommendations from a doctor.4 In 
contrast to the term “compliance,” adherence requires the patient’s agreement to the 
recommendation. Nonadherence is one of the major problems in glaucoma treatment. 
The reason is that there are no obvious symptoms in the earlier course for glaucoma 
patients.5 Furthermore, glaucoma medication may have negative side effects. Finally, 
the glaucoma patient usually requires a lifelong treatment but often does not realize 
any direct benefits from the therapy. However, nonadherence behavior has long-
term impacts on the visual function of the patient. Without hypotensive eye drops, 
an elevated IOP may lead to progressive optic nerve degeneration and deterioration 
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of the visual field.6,7 It is estimated that approximately 10% 
of visual field defects are caused by nonadherence.6 Addi-
tionally, nonadherence is associated with improper use of 
prescribed medication, which may lead to a further burden 
on our health–economic system.8
According to the literature, the rate of nonadherence in 
glaucoma therapy varies between 5% and 80%.5 The reason 
for this great variability of results is the heterogeneity in the 
measuring devices used and the definitions of adherence. 
Adherence can be measured by both electronic monitor-
ing devices or by analyses of questionnaires. For instance, 
the Travatan™ Dosing Aid Study9 demonstrated that the 
patients’ reported adherence rate was much higher than the 
rate measured by electronic monitoring devices. Furthermore, 
Konstas et al6 detected that 15% of glaucoma patients were 
unconscious of their nonadherence, which meant that the 
patients were taking their prescribed glaucoma medication 
at the right time but were unable to apply their eye drops 
properly. Another possible reason for nonadherence is poor 
knowledge about the disease. One previous study10 postu-
lated that good knowledge about glaucoma may positively 
influence patients’ adherence. Several studies6,10,11 showed 
that many glaucoma patients had little knowledge about their 
disease. Konstas et al6 demonstrated that only half of their 
patients knew the definition of glaucoma and only a quarter 
of their patients were knowledgeable about the fact that 
glaucoma can potentially lead to blindness.
The goal of the current study was to determine the adher-
ence of glaucoma patients by self-reporting questionnaires. 
Furthermore, we examined the relationships between the 
adherence behavior and the patients’ demographic data, 
clinical characteristics, and knowledge about glaucoma. 
This information may help to identify potential predictors 
of adherence in glaucoma therapy.
Subjects and methods
Design
A prospective, questionnaire-based study of a consecutive 
sample of patients with POAG was conducted from April to 
October 2010 at the University Eye Clinic, Friedrich-Alexander 
University, Erlangen, Germany. Patients were included in this 
study if they had had a topical medical therapy for POAG 
for at least 4 weeks. Exclusion criteria were other types of 
glaucoma (eg, congenital, closed-angle glaucoma, or sec-
ondary glaucoma), eye diseases interfering with glaucoma 
management, a history of dementia or cognitive restrictions, 
language barriers, or a disability of reading and writing. At the 
first point of measurement (T1), the patients were asked to fill 
in a standardized questionnaire at the University Eye Clinic, 
Friedrich-Alexander University, Erlangen. Two months later 
(T2), the patients were requested to answer a second standard-
ized questionnaire at home and send it back to the hospital 
by mail. The reason to choose the time point T2 as 2 months 
after T1 was to avoid the influence of scheduled visits to the 
ophthalmologist on the patients’ answers in the questionnaire. 
In our sample, most glaucoma patients had scheduled their 
visits every 3 months. This study was performed in accordance 
with the ethical standards laid down in the 1964 Declaration 
of Helsinki and was approved by the local ethics committee, 
Friedrich-Alexander University, Erlangen, Germany. Written 
informed consent from the patients was obtained for including 
their data into this study.
In total, 244 patients were considered for participation in 
this study. Of the 244 patients, 123 patients completed this 
study until the end of the follow-up period. Of the remaining 
121 patients, 40 patients were excluded based on the exclu-
sion criteria, eight patients refused to participate, 60 patients 
did not complete the questionnaire at T1, and 13 patients 
did not answer the questionnaire at T2. POAG was defined 
as an increase in IOP $22 mmHg (measured by Goldmann 
applanation tonometry) and documented optic disk changes 
and/or visual field defects consistent with glaucoma. Glau-
comatous optic disk changes were progressive optic disk 
cupping, asymmetric optic disk cupping (.0.2 difference), 
optic disk hemorrhage, acquired pit of the optic nerve, para-
papillary retinal nerve fiber layer loss, and large cup-to-disk 
ratio (thin neuroretinal rim).
Baseline demographic and clinical data were obtained 
from each patient. The following demographic information 
was requested from the patients: age, sex, marital status, 
living situation, educational level, and employment status. 
Furthermore, the following clinical information was collected 
from the medical records: first time of diagnosis of glaucoma, 
current and maximal IOP measured by Goldmann applana-
tion tonometry, best-corrected visual acuity using standard-
ized acuity charts, slit-lamp biomicroscopy, gonioscopy, 
optic disk changes according to Jonas’ classification,12 and 
visual field defects measured by white-on-white Humphrey 
30-2 visual tests. The severity of glaucoma was assessed 
using the clinical data, including visual acuity, visual field 
defects, and optic disk changes. The extent of visual field 
defects was assessed according to Mills’ classification.13 
Patients with progressive visual field defects received a 
Goldmann perimetry and were classified as stage 5 of Mills’ 
classification. The severity of optic disk changes was assessed 
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Adherence to glaucoma eye drops
disease was estimated by the patients’ 24-hour IOP profiles, 
temporal changes in visual field defects, and evaluation by 
their ophthalmologists.
Measures
At time point T1, the patients were asked to fill in the first 
questionnaire, which comprised the following self-reported 
measures: knowledge assessment, Adherence to Refills 
and Medication Scale 2 (ARMS2), visual analog scale for 
adherence (VAS-AD), and missed doses in the past 14 days. 
Two months later at time point T2, the patients were given a 
second questionnaire, which reevaluated ARMS2, VAS-AD, 
and missed doses in the past 14 days.
Assessment of knowledge of glaucoma patients
The knowledge assessment test was developed according to 
the studies of Blondeau et al14 and Hoevenaars et al.15 The test 
contained ten specific questions about glaucoma, eg, “Can 
glaucoma lead to blindness?” or “Does glaucoma affect the 
visual field?” All questions reflected essential parts of the 
disease and its therapeutic options and could potentially be 
answered by glaucoma patients. The answering scale was 
“no”, “yes”, and “I do not know”.
ArMs score
The ARMS tool of Kripalani et al16 examined adherence to 
medication in terms of two points: correct form and refill of 
medication, and correct intake of medication. In particular, 
the questions were developed in such a way that they were 
independent of the literacy of the patients. For this study, we 
created a German-translated and adapted version (ARMS2) 
of the original version. The validity was determined by cor-
relation with the widely used Morisky scale. The English 
original version included four items containing prescription-
refill subscales and eight items containing medication-taking 
subscales. The 12 items of the original version were answered 
on a four-point Likert scale, with the answering options 
“never,” “sometimes,” “mostly,” and “always.” We chose 
a ten-step numeric rating scale, with 0 meaning “never” 
and 9 meaning “always” for a better differentiation of the 
answers and adaptation to the remainder of the questionnaire. 
For the total result of ARMS, all values above zero reflected 
some degree of nonadherence. The number 1 meant little 
nonadherence and 99 meant absolute nonadherence, which 
is equivalent to a rejection of therapy.
The English version of ARMS was validated in the study 
“Improving medication adherence through graphical enhanced 
interventions in coronary heart disease” (IMAGE-CHD).16 As 
a criterion of reliability, the authors reported a good internal 
consistency and test–retest reliability. Cronbach’s alpha was 
0.81; the test–retest reliability was 0.69.
Adherence assessment by VAs-AD, and missed doses
To assess the adherence of patients to topical glaucoma 
medication, different question-and-answer formats were 
developed to decrease the risk of providing distorted informa-
tion in the self-reporting questionnaires. In a VAS-AD, the 
patients should indicate how often they took their eye drops 
as recommended. They were asked to set their answer on a 
10 cm horizontal line, with 0 cm representing “never” and 
10 cm representing “always.” Similar to the questionnaires 
of Pappa et al17 and Kholdebarin et al18 the patients had to 
answer the question about how often they forgot the doses 
in the past 14 days. The patients recorded the application of 
eye drops. Furthermore, they had to specify the frequency 
of daily eye drop dosage.
statistical analysis
Statistical analyses were conducted with the SPSS software ver-
sion 18.0 (SPSS; Chicago, IL, USA). Descriptive statistics were 
used for the calculation of mean values and standard deviations 
(SDs) at time points T1 and T2. Bivariant correlations were 
assessed by analyses of dependent and independent variables. 
Regression models were used to assess the predictability of the 
independent variables of adherence. Only data with at least one 
of the adherence measures ARMS2 or VAS-AD were included 
in the analyses. In subscales with up to eight items, two missing 
items were accepted. In the subscales with at least eleven items, 
a maximum of 20% missing items was accepted. Missing values 
were substituted by the mean value of the remaining values. 
P,0.05 was regarded as statistically significant.
Results
Basic demographics and clinical 
characteristics
Among a total of 123 patients, there were 78 females (63.4%) 
and 45 males (36.6%). The mean age was 67.0±13.7 years 
(range: 45–88 years). Majority of the patients were living 
with their partners and had retired. Moreover, 74% of patients 
(n=91) still lived with their partners, 23.6% of patients (n=29) 
had lived in a partnership, and 2.4% of patients (n=3) were 
living alone. Concerning the employment status, 70.7% of 
patients (n=87) had retired, 12.2% of patients (n=15) were 
still full-time employees, 10.6% of patients (n=13) had part-
time employment, and 6.5% of patients (n=8) had no work. 
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general school certificate, 25.2% of patients (n=31) had a high 
school diploma, 13.8% of patients (n=17) a higher education 
entrance qualification, and 5.7% of patients (n=7) had other 
kinds of educational qualifications.
The  mean  IOP a t  T1  was  13 .4±3.1  mmHg 
(range: 7–28 mmHg) in the better eye and 15.6±3.8 mmHg 
(range: 8–36 mmHg) in the worse eye. The visual acuity 
at T1 was 0.8±0.2 (range: 0.2–1.2) in the better eye and 
0.5±0.3 (range: 0.1–1.0) in the worse eye. Blindness in one 
eye was present in 4.9% of patients (n=6). The distribution 
of the visual field defects according to Mills’ classification 
is shown in Figure 1. The distribution of optic disk changes 
according to Jonas’ classification is depicted in Figure 2.
Among the excluded subjects, the mean age of the patients 
who refused to complete the questionnaire was significantly 
higher than that of the study participants (P=0.005). There 
was no significant age difference between the study partici-
pants and the patients with incomplete questionnaires (drop-
outs) (P=0.743). The sex distribution was even in all groups 
(P=0.804). The mean IOP of the worse eye of the dropouts 
was significantly higher than that of the study participants 
(P=0.006). In contrast, the mean IOP of the better eye was simi-
lar in all groups. Patients refusing to fill out the questionnaire 
had significantly more visual field defects in both the better and 
the worse eyes (P=0.004 and P=0.005). However, the adher-
ence measures were similar between the participants and the 
nonparticipants at T2 (VAS: P=0.624; ARMS: P=0.064).
Assessment of knowledge  
of glaucoma patients
On average, seven out of ten questions in the knowledge 
assessment questionnaire were answered correctly. However, 
only 8.2% of patients answered all questions correctly. More 
than 95% of patients knew about the fact that glaucoma can 
lead to visual field defects and blindness. Approximately half 
of the patients knew that vision loss is irreversible, although 
24.6% of patients believed that glaucoma could be cured. The 
most common false assumption made by 80% of patients was 
that vision loss could only be caused by an increase in IOP.
Medication adherence
To determine the medication adherence of glaucoma patients, 
three adherence measures were studied at both time points 
T1 and T2: ARMS2, VAS-AD, and missed doses in the past 
14 days. The descriptive values of the adherence measure scales 
are displayed in Table 1. We found a good correlation among 
all three adherence measures at both time points T1 and T2 
(Table 2). The mean values of ARMS2 were in the lower range, 
with 3.38 at T1 and 2.8 at T2. The mean values in ARMS2 did 
not significantly vary between T1 and T2 (P=0.335). In our 
study group, the most common reason for nonadherence was 
forgetfulness, reported by 43.8% of patients (Figure 3). One 
third of patients missed doses if they had to apply eye drops 
more than once a day. Inattentiveness as the reason of nonadher-
ence was identified in 25% of the study participants.
In the VAS-AD, the subjects were asked to indicate how 
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Figure 2 Stages of optic disk changes according to Jonas’ classification in the study 
group.




Possible values N T1 T2
Mean SD Mean SD
ArMs2 0–99 120 3.38 (6.89) 2.80 (4.05)
VAs-AD 0.0–10.0 116 9.03 (1.34) 9.08 (1.03)
Missed doses starting from 0 113 0.37 (0.81) 0.50 (1.08)
Abbreviations: ARMS2, Adherence to Refills and Medication Scale, German-
translated version; SD, standard deviation; T1, first point of measurement; T2, second 
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Adherence to glaucoma eye drops
values of VAS-AD were 9.03 at T1 and 9.08 at T2 (Table 1). 
They were similar between T1 and T2 (P=0.735). At T1, 
18.5% of patients indicated that they always took the eye 
drops correctly; 68.9% of patients had a correct intake in at 
least 90% of occasions.
The average missed doses in the past 14 days showed 
the lowest variance: 77.9% of patients indicated that they 
did not miss a single dose in the past 14 days. Two months 
later, 74.2% of patients did not miss a single dose in the 
past 14 days. The mean number of missed doses at T1 was 
0.37 doses in the past 14 days. At T2, the patients had missed a 
mean of 0.50 doses in the past 14 days (Table 1). These values 
were also stable during the follow-up period (P=0.110).
correlation between demographic/
clinical characteristics and adherence
To analyze whether demographic or clinical characteristics 
influence the adherence behavior of glaucoma patients, we 
correlated them with ARMS2 and VAS-AD at both time 
points T1 and T2 (Table 3). For the demographic data, we 
did not find any significant correlations between the patients’ 
age (P=0.1), sex (P=0.23), or educational level (P=0.21) and 
the adherence measures ARMS2 or VAS-AD. Among the 
clinical characteristics, only blindness showed a significant 
correlation with VAS-AD (P=0.008). Single-eye blindness 
was associated with fewer correct applications of eye drops. 
Other clinical parameters such as IOP, visual acuity, visual 
field defects, and optic disk changes did not correlate with 
ARMS2 or VAS-AD.
correlation between knowledge 
of glaucoma and adherence
The descriptive values of the knowledge assessment only 
showed a weak correlation with the adherence measures 
ARMS2 and VAS-AD at both time points T1 (ARMS2: -0.08; 
VAS-AD: -0.05) and T2 (ARMS2: -0.07; VAS-AD: 0.04).
Discussion
In this study, we investigated patients’ adherence to topi-
cal eye drops by using three different adherence measures. 
There was a good correlation among ARMS2, VAS-AD, 
and missed doses in the past 14 days. Therefore, it can be 
assumed that all three measures assessed the same construct 
of adherence. The descriptive values of all three measures 
demonstrated that most patients in our study group were 
adherent to their topical glaucoma medication. There were 
no significant changes in the adherence behavior between the 
first evaluation at hospital (T1) and the second one 2 months 
later at home (T2). We chose the time interval of 2 months 
between time points T1 and T2 because we wanted to avoid 
the influence of the eye doctor’s visits on the adherence 
behavior. In a study by Kass et al19 it could be demonstrated 
that there was a significant increase in the adherence rate 
24 hours before an appointment with the ophthalmologist. 
Unfortunately, many of our patients reported paying a visit 
to their ophthalmologist right after answering the second 
questionnaire. Therefore, it would have been better to set the 
time point T2 in a more individualized time schedule. This 
would have helped obtain adherence data independent of a 
doctor’s appointment. Further studies are certainly required 
to observe the adherence behavior of glaucoma patients dur-
ing a long-term follow-up period.
In previous studies, adherence barriers were divided into 
patient-related, disease-related, and therapy-related factors. 
The patient-related factors include demographic data of 
the patient such as sex or educational level. Previously, a 
significant correlation was detected between the male sex 
and nonadherence.6,20 Kholdebarin et al18 found a positive 
association between low educational level and nonadherent 
behavior. In this study, we could not detect any significant 
Table 2 correlations of the adherence measures at T1 and T2
Measures, (n) T1 T2
(1) (2) (3) (1) (2) (3)
ArMs2, (1) 1 nA nA 1 nA nA
VAs-AD (P-value), (2) -0.41 (0.007) 1 nA -0.31 (0.006) 1 nA
Missed doses (P-value), (3) 0.43 (0.006) -0.47 (0.007) 1 0.53 (0.008) -0.28 (0.008) 1
Abbreviations: ARMS2, Adherence to Refills and Medication Scale, German-translated version; NA, not applicable; T1, first point of measurement; T2, second point of 
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correlations between demographic factors and the adherence 
behavior of our study participants. One reason for this might 
be the differences in patient population. The patients in our 
study had a long history of glaucoma and were relatively 
well informed. Therefore, demographic factors might have 
less influence on the adherence behavior in our specific study 
group. Disease-related adherence barriers include visual 
acuity, visual field defects, and blindness. A previous study10 
has shown that patients were more adherent to medication if 
they had worse visual field defects or were blind in one eye. 
However, blindness in both eyes apparently reduced the 
adherence rate because both-eye-blinded patients are prob-
ably more dependent on the help of a third person.21 In this 
study, single-eye blindness was associated with worse 
adherence values as measured by VAS-AD. A relationship 
between the severity of disease and the adherence behavior 
was also previously described.22 In particular, the severity 
of glaucoma was assessed using clinical parameters such as 
visual acuity, visual field defects, and optic disk changes. 
We could not detect any significant correlation between 
visual acuity, visual field defects, or optic disk changes 
and adherence behavior. However, most of our patients 
had only early stages of glaucoma, so that few patients of 
our study group were actually affected by severe visual 
impairment. Therefore, it remains unclear whether these 
clinical parameters may influence the adherence behavior 
of glaucoma patients in general.
Another factor that may influence the adherence behav-
ior is the patients’ knowledge about their disease. In the 
1970s, Spaeth10 observed that patients took their eye drops 
less often in a correct manner if they were insufficiently 
knowledgeable about glaucoma. This observation could not 
be confirmed in the current study. However, it must be taken 
into account that our patients represented a well-informed 
group. More than 90% of our study participants had good 
knowledge about glaucoma. Therefore, an increase in 
knowledge would probably have no additional influence 
on the adherence behavior. However, our results could not 
predict whether patients’ knowledge about glaucoma may 
affect the adherence behavior in other glaucoma patients. 
Hoevenaars et al15 also did not find a significant correla-
tion between patients’ knowledge about glaucoma and 
their adherence behavior. They even showed that know-
ing the fact that glaucoma is a slowly progressive disease 
was associated with lower adherence to the medication. 
Until now, no clear correlation between patients’ knowl-
edge of glaucoma and their adherence behavior has been 
demonstrated.15
One limitation of our study was to have excluded glau-
coma patients who did not meet the inclusion criteria. Besides 
that, our results relied on self-reporting questionnaires of 
glaucoma patients, who may tend to give socially compat-
ible answers. Other limitations were the small sample size 
of patients and the period between T1 and T2. In addition, 
environmental factors, social support, and overall medication 
regimen were also not identified. Furthermore, no second 
group of participants was added as a control group to this 
study. Finally, the questionnaire was only administered to 
patients of a university hospital, which may not represent 
the general population of patients with glaucoma. Therefore, 
studies that are more extensive with greater sample sizes, 
longer assessment period, and objective measurements of 
adherence are planned in the future.
In summary, we could not show any strong influence of 
the patients’ demographic data, their clinical characteristics, 
or their knowledge about glaucoma on their medication 
adherence. Probably, there are no general rules and more 
individualized strategies are required to optimize adher-
ence behavior. Individualized patient care already has the 
potential to improve adherence to glaucoma therapy.23 
Therefore, it will become more important to assess the 
health-care needs and patient’s views on glaucoma before 
prescribing antiglaucomatous eye drops. Furthermore, 
this study also demonstrates the difficulty in measuring 
the adherence rate to medication independent of doctor’s 
appointments. Assuming that doctor’s visits may influence 
medication adherence, a broader use of reminder systems 
such as phone call reminders may help to improve patients’ 
adherence behavior.
Table 3 correlations between demographic/clinical factors and 
adherence
T1 T2
ARMS2 VAS-AD ARMS2 VAS-AD
Demographic factors
Age -0.13 0.09 -0.14 0.04
sex -0.01 -0.06 0.01 0.05
education -0.08 0.08 -0.07 0.03
clinical factors
iOP 0.01 -0.01 -0.09 0.15
Maximal iOP -0.09 0.07 -0.13 -0.13
Visual acuity -0.03 -0.03 0.05 -0.02
Stage of visual field defects 0.04 0.09 -0.09 0.04
stage of optic disk changes -0.01 0.04 -0.09 -0.01
Blindness 0.12 -0.27** 0.01 -0.05
Notes: **P,0.01.
Abbreviations: ARMS2, Adherence to Refills and Medication Scale, German-translated 
version; IOP, intraocular pressure; T1 , first point of measurement; T2, second point 
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